Triggers for atopic dermatitis include exposure to allergens such as pollen, pet dander, or peanuts, as well as stress, dry skin, or infections. At Almirall, we understand the complex relationship between atopic dermatitis and allergies. Through innovation and collaboration with patient associations and the dermatological community, we seek to continue to move towards a better future for people with atopic dermatitis. For more information, visit https://lnkd.in/d7c55bhY #AtopicDermatitis #MedicalDermatology
Sobre nosotros
Almirall is a global biopharmaceutical company focused on medical dermatology. Founded in 1944 and with headquarters in Barcelona (Spain), our purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. Through pharmaceutical innovation, investment in R&D and strong commitment to global healthcare partnerships, we develop and commercialize solutions with specific focus on dermatological diseases such as psoriasis, actinic keratosis, atopic dermatitis or acne. We care and listen to our patients’ needs. We find solutions for them. We aim to empower them. Almirall has 1 R&D center, 2 chemical plants and 2 pharmaceutical plants. Our more than 1,900 employees make it possible for our treatments to be available in over 100 countries across 5 continents, through our 15 global affiliates and via a strategic partnership network. Almirall is listed on the Spanish Stock Exchange (ticker: ALM).
- Sitio web
-
http://www.almirall.com
Enlace externo para Almirall
- Sector
- Fabricación de productos farmacéuticos
- Tamaño de la empresa
- De 1.001 a 5.000 empleados
- Sede
- Barcelona
- Tipo
- Empresa pública
- Fundación
- 1944
- Especialidades
- Dermatology (Actinic keratosis, Atopic Dermatitis, Eczema, Inflammatory Skin Conditions, Psoriasis, Rosacea, Severe Acne), OTC Products, Other Specialty Areas (e.g. Spasticity in Multiple Sclerosis) y Medical Device
Ubicaciones
-
Direktorin
Ronda General Mitre, 151
Barcelona, 08022, ES
-
Carretera Laureà Miró, 408
Sant Feliu de Llobregat, Barcelona 08980, ES
-
Carretera de Martorell 41-61
Sant Andreu de la Barca, Barcelona 08740 , ES
Empleados en Almirall
Actualizaciones
-
Last month, we introduced #Act4Impact, our updated sustainability strategy setting ambitious targets for 2030. This comprehensive approach is at the heart of our decision-making and aligned with our purpose of transforming patients' lives. Sustainability News interviewed our Global Sustainability Senior Manager, Cristina Raventós, to discuss the pharmaceutical industry’s sustainability journey and how our Act4Impact strategy is driving positive change. Read the full interview here: https://lnkd.in/e2iEhDSm #Act4Impact
-
-
Technologies such as #mRNA are set to transform the industry and the way drugs are developed. This technology, which gained momentum during the pandemic and is now increasingly seen as a valuable therapeutic modality, could help address current unmet medical needs from different angles at once. Last year, we entered into a multi-target alliance with etherna to discover and develop novel mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The flexibility of mRNA technology will allow us to explore new therapeutic hypotheses in different disease indications and help us move closer to our purpose of improving people's lives. #Innovation #MedicalDermatology
-
-
Don't let myths about actinic keratosis put your skin at risk this summer! 🔹Myth 1: Actinic keratosis isn’t dangerous. 🔹Myth 2: Actinic keratosis does not require treatment. 🔹Myth 3: Skin cancer is not life-threatening. The truth is that actinic keratosis is a precancerous condition that may turn into squamous cell carcinoma if untreated. Skin cancer is the most common form of cancer in the United States and can be life-threatening. Protect your skin this summer by being aware of the dangers of actinic keratoses, and visit your doctor for an early diagnosis. For more information, you can visit: https://lnkd.in/dqcNzXaz #ActinicKeratosis #CheckYourSkin #StayVigilant
-
-
"This is a first step in better understanding the pathogenesis of hidradenitis suppurativa at the molecular level. We need to continue to build on these findings to generate new hypotheses for drug discovery on the road to finding new effective treatment options for patients suffering from HS," stated our Disease Biology scientists Marta Calbet and Ozge Uluckan. 📖Have you read our scientists' interview in Dermatology Times about the latest developments in our collaboration with the University of Michigan? Learn here how these research efforts pave the path towards addressing the unmet needs of people with skin diseases like HS and improve their wellbeing: https://lnkd.in/dsgay-6K #Innovation #MedicalDermatology #HidradenitisSuppurativa
-
-
Summer is here, so don't let actinic keratosis ruin your fun in the sun! 🚩These rough, raised bumps on your skin can be a red flag and a warning sign of something more serious. Actinic keratosis is a skin condition caused by prolonged exposure to UV rays from the sun and tanning beds. But don't worry; you can still enjoy the summer while protecting your skin. Reduce your risk by using sunscreen every day and limiting your exposure to the sun. Stay safe during this summer season! For more information, you can visit https://lnkd.in/dqcNzXaz #ActinicKeratosis #CheckYourSkin #StayVigilant
-
-
🤝 Act4Impact: Our strategy towards our partners Through the "Partners" pillar of our #Act4Impact 2030 strategy, we aim to have at least 75% of our spending covered by ESG-audited suppliers by 2030. To achieve this, we will deploy our sustainable procurement program through an enhanced Supplier Risk Management Process, implement tools and platforms to support the process, ensure effective governance, and reinforce sustainability-related aspects in our relationship with our value chain. We will do this to ensure that more than 69% of our emissions come from suppliers with a carbon scorecard. Join us on this journey towards a meaningful and lasting difference in society and the environment! #Act4Impact #Sustainability
-
This month, we celebrated #SmartDay, an event where our teams could learn and test the latest digital tools that make our work easier and allow us to be more collaborative, efficient, and data-driven. This event was promoted by Smart Workplace, our Digital Workplace adoption program that motivates people to take advantage of technology and make the most of it. 👏🏽 More than 100 people participated, and we had workshops of all kinds, with #AI being the main topic. We thank all the people who participated and encourage everyone to explore the possibilities that our Digital Capabilities offer. At Almirall, we have been innovating for 80 years to offer quality solutions to patients and society, and we will continue to do so with the support of technology that makes us smarter and more agile. #WeAreAlmirall #Innovation #DigitalWorkplace
-
-
We are thrilled to announce that EcoVadis has awarded us once again the Platinum Medal for 2024, recognizing our steadfast commitment to sustainability. With an outstanding score of 87 out of 100, we are placed among the top 1% of companies assessed in our industry, reaffirming our leadership across four core themes: Environment, Labor & Human Rights, Ethics and Sustainable Procurement. This achievement drives us to continue deepening our sustainability and ESG efforts, striving to positively impact the environment, society, and our patients. #Act4Impact
-
-
🙌 Act4Impact: Our strategy for patients Our goal is to keep positively impacting people with skin conditions through our dermatology portfolio. This is a key strategic objective for our company. As part of our sustainability strategy, #Act4Impact 2030, we aim to enhance our engagement with patients, particularly focusing on the wellbeing of our dermatology patients. By fostering a patient-centric mindset throughout the company, we prioritize patients' needs and place them at the core of our decision-making process. Together, we can make a significant and lasting difference to society. #Act4Impact #Patients #TogetherWeCare
Páginas similares
Buscar empleos
Financiación
Última ronda
Equidad tras OPV215.792.796,00 US$